Monograph
R01AD05 - Budesonide |
Not porphyrinogenic |
NP |
Rationale
Probably insignificant systemic exposure. Several references stating non-porphyrinogenicity of glucocorticoids.
Chemical description
Glucocorticoide with strong antiinflammatory effect used in nasal spray in allergic and vasomotor rhinitis. The amount of budesonide in each dose is 50 - 100 µg. Systemic exposure 33%. Used in porphyria ward (Sweden). EPI-list: safe French list: authorized. South African list: use Kalman, Bonkowski: safe The Merck Manual: safe Tschudy DP, Lamon JM: Porphyrin metabolism and the porphyrias, in Bondy PK, Rosenberg LE (eds.): Duncan's Diseases of Metabolism. Philadelphia, WB Saunders, 1980, p939: safe Moore MR, Hift RJ: Drugs in the acute porphyrias. Cell Mol Biol 43:89, 1997: safe
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Poland
Finland
Latvia© NAPOS 2024